CORESTEM Inc Total Liabilities

Latest as of September 2025: ₩72.65 Billion KRW ≈ $49.24 Million USD

CORESTEM Inc total liabilities. Based on the latest financial reports, CORESTEM Inc (166480) has total liabilities worth ₩72.65 Billion KRW (≈ $49.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CORESTEM Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of CORESTEM Inc (2014–2024)

Total liabilities of CORESTEM Inc from 2014 to 2024. This chart illustrates how CORESTEM Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 166480 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

CORESTEM Inc Competitors by Total Liabilities

The table below lists competitors of CORESTEM Inc ranked by their total liabilities.

Company Country Total Liabilities
CID HoldCo, Inc. Common Stock
NASDAQ:DAIC
USA $9.56 Million
Uniti SA
PA:ALUNT
France €284.01 Million
Kyung Chang Industrial Co. Ltd
KQ:024910
Korea ₩379.37 Billion
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
USA $101.01 Million
Pion Group AB Series B
ST:PION-B
Sweden Skr327.60 Million
HICL Infrastructure Company Ltd
LSE:HICL
UK GBX4.70 Million
Gome Telecom Equipment Co Ltd
SHG:600898
China CN¥302.78 Million
PTRB
KLSE:0260
Malaysia RM184.59 Million

Liability Composition Analysis (2014–2024)

This chart breaks down CORESTEM Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CORESTEM Inc assets under control.

Liquidity & Leverage Metrics

CORESTEM Inc Total Liabilities Ratios Explained

CORESTEM Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.64 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CORESTEM Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CORESTEM Inc (2014–2024)

The table below shows the annual total liabilities of CORESTEM Inc from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩68.86 Billion
≈ $46.67 Million
+16.74%
2023-12-31 ₩58.99 Billion
≈ $39.98 Million
+58.78%
2022-12-31 ₩37.15 Billion
≈ $25.18 Million
-62.55%
2021-12-31 ₩99.22 Billion
≈ $67.24 Million
-2.33%
2020-12-31 ₩101.59 Billion
≈ $68.84 Million
+263.43%
2019-12-31 ₩27.95 Billion
≈ $18.94 Million
+3.43%
2018-12-31 ₩27.03 Billion
≈ $18.31 Million
+7.80%
2017-12-31 ₩25.07 Billion
≈ $16.99 Million
+32.22%
2016-12-31 ₩18.96 Billion
≈ $12.85 Million
+59.12%
2015-12-31 ₩11.92 Billion
≈ $8.08 Million
-29.97%
2014-12-31 ₩17.02 Billion
≈ $11.53 Million
--

About CORESTEM Inc

KQ:166480 Korea Biotechnology
Market Cap
$30.92 Million
₩45.63 Billion KRW
Market Cap Rank
#23470 Global
#1613 in Korea
Share Price
₩1624.00
Change (1 day)
+1.69%
52-Week Range
₩1060.00 - ₩4800.00
All Time High
₩32150.00
About

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more